Indivior Appoints Joe Ciaffoni as New CEO: A Strategic Move for Addiction Treatment

Indivior PLC (Nasdaq/LSE: INDV) has announced the appointment of Joe Ciaffoni as its new Chief Executive Officer, effective upon shareholder approval at the May 2025 AGM. Ciaffoni, 53, who joined as an Independent Non-Executive Director in December 2024, brings over 30 years of experience in pharmaceuticals and biotech, having previously served as President and CEO of Collegium Pharmaceutical. His appointment aims to fuel Indivior's next growth phase in addiction treatment, where the company maintains a global portfolio of OUD treatments and employs over 1,000 individuals with products available in more than 30 countries.

Current CEO Mark Crossley will step down following his tenure since June 2020, but will remain to support the transition until at least May 2025. Under Crossley's leadership, the company has strengthened its commitment to patients, expanded access to treatment, and advanced its mission of pioneering life-transforming treatments for substance use disorders.

Ciaffoni's appointment aligns with Indivior's strategic vision and long-term growth plans, as he brings a proven track record of operational and strategic success across diverse models and therapeutic areas. His experience in specialty, rare disease, mass market, and hospital sectors, along with his expertise in addiction treatment, positions him well to drive Indivior's growth and deliver positive outcomes for patients while generating shareholder value.

David Wheadon, Chair of Indivior's Board of Directors, said: "We are delighted to appoint Joe as our next Chief Executive Officer. He is an accomplished leader with a strong track record of delivering positive outcomes for patients while generating shareholder value. He has a clear mandate to fuel the next stage of Indivior's growth and deliver on the Company's significant potential and we look forward to supporting his success as CEO."

Joe Ciaffoni said: "It is an honor to be appointed as CEO. Indivior is a leader in the addiction treatment space and its work has never been more necessary. I look forward to working with the team to deliver on the Company's potential and to drive Indivior's future growth for the benefit of all our stakeholders."



Indivior's financial achievements in 2024 highlight the company's ongoing commitment to developing innovative treatments for substance use disorders (SUD). Through a global approach, Indivior works diligently to ensure that patients have access to effective treatments that address these chronic conditions. Key financial highlights include:

* Increased revenue, driven by the ongoing demand for the company's portfolio of products aimed at treating opioid use disorder (OUD)
* Focus on research and development (R&D), with a robust pipeline of product candidates designed to expand the company's offerings in addiction treatment
* Corporate strategy and vision centered around ensuring that all patients have access to evidence-based treatments for SUD, transforming these conditions into recognized and treated chronic diseases

Indivior's roadmap for the future includes an unwavering focus on enhancing its treatment portfolio, innovation, and addressing the global crisis of substance use disorders. By leveraging technological advancements and engaging with healthcare systems worldwide, Indivior aims to pave the way for new treatment modalities that improve patient outcomes.

In conclusion, Joe Ciaffoni's appointment as CEO of Indivior PLC signals a strategic move for the company's next growth phase in addiction treatment. With his extensive experience in the pharmaceutical and biotech industries, Ciaffoni is well-positioned to drive Indivior's growth and deliver positive outcomes for patients while generating shareholder value. The company's commitment to patients and access to treatment for substance use disorders remains steadfast, as it continues to develop innovative therapies and expand its global footprint.